Lehmann's team divided TNBC into the following subtypes by gene expression profile of tumor samples from 587 patients with TNBC, including basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal-like (MES), mesenchymal/stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) [24]. This evidence concerns the gene PTPRF and neoplasm.